Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
<h4>Background</h4> <p>Negative symptoms of schizophrenia represent deficiencies in emotional responsiveness, motivation, socialisation, speech and movement. When persistent, they are held to account for much of the poor functional outcomes associated with schizophrenia. There are...
Κύριοι συγγραφείς: | Barnes, T, Leeson, V, Paton, C, Costelloe, C, Simon, J, Kiss, N, Osborn, D, Killaspy, H, Craig, T, Lewis, S, Keown, P, Ismail, S, Crawford, M, Baldwin, D, Lewis, G, Geddes, J, Kumar, M, Pathak, R, Taylor, S |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
National Institute for Health Research
2016
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial
ανά: Thomas RE Barnes, κ.ά.
Έκδοση: (2016-04-01) -
Long-term antidepressant treatment for negative symptoms in schizophrenia: the actions study
ανά: Barnes, T, κ.ά.
Έκδοση: (2017) -
Disclosing the potential impact of placebo controls in antidepressant trials
ανά: Stephanie C. Chen, κ.ά.
Έκδοση: (2015-06-01) -
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness
ανά: Thomas RE Barnes, κ.ά.
Έκδοση: (2017-09-01) -
Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.
ανά: Crawford, A, κ.ά.
Έκδοση: (2014)